Financial releases

Commercial agreement with DESITIN Pharma for ZENEO® Midazolam in Germany

End of the conversion of convertible bonds issued in 2018

Crossject - Slideshow Annual results 2018

Financial results 2018

CROSSJECT- Gain of pharmaceutical establishment status

Crossject : €1.1 million in funding granted jointly by Bpifrance and the Bourgogne Franche-Comté region

SUCCESS OF THE €4 MILLION CAPITAL INCREASE

Business update November 2018

Strengthening of pharma skills within the Crossject supervisory board

First-half 2018 results and business update